Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

PharmacoEconomics

Volumn 23, Issue 5, 2005, Pages 515-526

  Dalziel, Kim ^a   Round, Ali ^a   Garside, Ruth ^a   Stein, Ken ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; IMATINIB;

ARTICLE; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MARKOV CHAINS; MODELS, ECONOMIC; PIPERAZINES; PYRIMIDINES;

EID: 22244468056     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200523050-00010     Document Type: Article

References (29)

1. Kumar P. Clinical medicine. 4th ed. Clin Med 2001; 4: 425-32
2. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330-40
3. Hernandez-Boluda JC, Cervantes F, Alvarez A, et al. Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. Ann Hematol 2001; 80: 516-20
4. Delannoy A, Kluin-Nelemans JC, Louwagie A, et al. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89 (21): 1616-20
5. Kalidas M, Kantarjian H, Talpaz M. Chronic myelogenous leukemia. JAMA 2001; 286: 895-8S
6. Garside R, Round A, Dalziel K, et al. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review. Health Technol Assess 2002; 6 (33): 1-162
7. Talpaz M, Kantarjian HM, McCredie KB, et al. Clinical investi-gation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-8
8. Hehlmann R, Willer A, Heimpel H, et al. Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. Leukemia 1997; 11 Suppl. 3: 506-11
9. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood 1998; 92: 1541-8
10. Novartis Pharmaceuticals UK Ltd. Appraisal of Glivec for 1st line treatment of chronic myeloid leukaemia. Chamberley: Novartis Pharma AG, 2003 (data on file)
11. O'Brien SG, Guilhot F, Larson RA, et al., the IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004
12. Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. Blood 1998; 91: 2713-21
13. Dalziel K, Round A, Stein K, Garside R, et al. The effectiveness and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase. Monograph 70. London: National Institute for Clinical Excellence, 2003 Oct
14. Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. Ann Intern Med 1995; 122: 254-61
15. Bonifazi F. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074-81
16. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177-87
17. Bonifazi F, De Vivo A, Rosti G, et al. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Br J Haematol 2000; 111: 587-95
18. British National Formulary 44. London: British Medical Association and Royal Pharmaceutical Association of Great Britian, September 2002
19. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345: 1392-7
20. Kattan MW, Inoue Y, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125: 541-8
21. Gordois A, Scuffham P, Warren E, et al. Cost utility analysis of imatinib mesylate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003; 89: 634-40
22. Freund MG. Combination of chemotherapy and interferon alfa-2b in the treatment of chronic myelogenous leukemia. Semin Hematol 1993; 30: 11-3
23. Drummond M, McGuire A. Economic evaluation in health care. Oxford: Oxford University Press, 2001
24. Gambacorti-Passerini C, Gunby R, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75-85
25. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 2673-82
26. Messori A. A cost-effectiveness of interferon in chronic mye-loid leukaemia: analysis of four clinical studies. Ann Oncol 1998; 9: 389-96
27. Raftery J. Faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001; 323: 1300-3
28. European Agency for the Evaluation of Medicinal Products (EMEA). Procedure for orphan medicinal product designation: general principles. London: EMEA, 2002
29. Radford I. Imatinib. Novartis. Curr Opin Investig Drugs 2002; 3: 492-9